



## Prevail Therapeutics to Present at Upcoming Investor Conferences

September 2, 2020

### Citi 15th Annual BioPharma Conference, Morgan Stanley 18th Annual Global Healthcare Conference and Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- [Prevail Therapeutics Inc.](#) (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the Company will participate in the following upcoming virtual investor conferences in September:

- Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in a panel presentation at the Citi 15th Annual BioPharma Conference on Thursday, September 10 at 3:20 p.m. ET. The panel is titled "Disease-Modifying Therapies for Neurodegenerative Diseases."
- Dr. Abeliovich will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14 at 12 p.m. ET.
- Dr. Abeliovich will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 15 at 4:40 p.m. ET.

Webcasts of the presentations will be available under "Events and Presentations" in the Investors and Media section of the Company's website at [ir.prevailtherapeutics.com](http://ir.prevailtherapeutics.com) following the presentations.

#### About Prevail Therapeutics

Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The Company is developing PR001 for patients with Parkinson's disease with *GBA1* mutations (PD-GBA) and neuronopathic Gaucher disease; PR006 for patients with frontotemporal dementia with *GRN* mutations (FTD-GRN); and PR004 for patients with certain synucleinopathies.

Prevail was founded by Dr. Asa Abeliovich in 2017, through a collaborative effort with The Silverstein Foundation for Parkinson's with GBA and OrbiMed, and is headquartered in New York, NY.

#### Forward-Looking Statements Related to Prevail

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning the potential for Prevail's gene therapy candidates to transform the treatment of patients with, and slow or halt the progression of, FTD-GRN and other neurodegenerative diseases. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Prevail's novel approach to gene therapy makes it difficult to predict the time, cost and potential success of product candidate development or regulatory approval; Prevail's gene therapy programs may not meet safety and efficacy levels needed to support ongoing clinical development or regulatory approval; the regulatory landscape for gene therapy is rigorous, complex, uncertain and subject to change; the fact that gene therapies are novel, complex and difficult to manufacture; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in Prevail's filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2020, filed with the SEC on August 11, 2020, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Prevail undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

#### Media Contact:

Mary Carmichael  
Ten Bridge Communications  
[mary@tenbridgecommunications.com](mailto:mary@tenbridgecommunications.com)  
617-413-3543

#### Investor Contact:

[investors@prevailtherapeutics.com](mailto:investors@prevailtherapeutics.com)



Source: Prevail Therapeutics